Loading...
XKRX002390
Market cap120mUSD
Jan 08, Last price  
12,750.00KRW
1D
1.19%
1Q
-4.57%
Jan 2017
-51.43%
Name

Handok Inc

Chart & Performance

D1W1MN
XKRX:002390 chart
P/E
—
P/S
0.34
EPS
—
Div Yield, %
3.14%
Shrs. gr., 5y
0.30%
Rev. gr., 5y
3.19%
Revenues
522.74b
-3.87%
262,991,669,000275,094,854,000293,442,084,000321,036,497,000333,172,636,430314,647,672,880327,936,251,060348,310,911,100358,447,723,790396,134,013,870417,970,014,010446,731,040,930473,000,099,750503,611,879,690517,641,069,440543,759,151,910522,741,079,530
Net income
-28.80b
L
19,172,963,0006,826,263,00018,005,523,00020,530,093,00016,573,866,0005,768,268,88012,309,555,0001,473,262,320-1,687,149,450-6,454,088,0004,868,535,0807,989,532,35034,928,719,29026,959,657,8103,294,816,90010,683,543,860-28,797,445,620
CFO
35.98b
+17.88%
32,386,055,000-10,275,458,00024,194,802,00010,999,560,00048,084,918,31012,275,220,5509,278,933,57036,562,091,28014,640,167,760-8,501,956,0006,790,746,28029,455,780,1508,798,266,18024,341,172,26037,229,141,90030,519,188,79035,976,851,400
Dividend
Dec 27, 2023300 KRW/sh
Earnings
Feb 04, 2025

Profile

Handok Inc. operates as an integrated pharmaceutical company. The company provides ETC and OTC drugs, medical devices, and in-vitro diagnostics instruments and devices. It focuses on various therapeutic areas, such as oncology, diabetes and metabolic disorders, CNS orphan diseases, eye disorders, and other disease areas. The company also offers healthcare products comprising food supplements under the NatureSet and Culturelle brands; food and beverages; and medical nutrition products. Handok Inc. has a strategic collaboration agreement with AUM Biosciences Pte. Ltd. and CMG Pharmaceutical Co. Ltd. for the development, manufacturing, and commercialization of CHC2014, a pan-TRK inhibitor for cancer treatment. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is based in Seoul, South Korea.
URL
https://www.handok.co.kr/
IPO date
Jun 30, 1976
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
522,741,080
-3.87%
543,759,152
5.05%
Cost of revenue
460,841,461
451,567,794
Unusual Expense (Income)
NOPBT
61,899,618
92,191,358
NOPBT Margin
11.84%
16.95%
Operating Taxes
(4,567,445)
(3,279,675)
Tax Rate
NOPAT
66,467,063
95,471,033
Net income
(28,797,446)
-369.55%
10,683,544
224.25%
Dividends
(5,505,413)
(4,817,237)
Dividend yield
2.80%
2.09%
Proceeds from repurchase of equity
3,996,730
BB yield
-1.73%
Debt
Debt current
175,252,712
112,752,324
Long-term debt
126,469,422
186,781,335
Deferred revenue
176,607
25,870
Other long-term liabilities
14,844,440
15,041,392
Net debt
158,476,848
115,076,462
Cash flow
Cash from operating activities
35,976,851
30,519,189
CAPEX
(26,176,242)
(43,738,795)
Cash from investing activities
(49,717,587)
(63,500,221)
Cash from financing activities
(6,392,188)
39,831,712
FCF
70,257,035
59,782,947
Balance
Cash
20,055,041
39,845,842
Long term investments
123,190,245
144,611,355
Excess cash
117,108,232
157,269,239
Stockholders' equity
236,673,221
411,535,674
Invested Capital
538,556,779
529,462,544
ROIC
12.45%
19.00%
ROCE
9.32%
13.09%
EV
Common stock shares outstanding
13,770
13,770
Price
14,300.00
-14.63%
16,750.00
-26.54%
Market cap
196,904,322
-14.63%
230,639,678
-26.54%
EV
357,282,325
347,759,709
EBITDA
84,387,882
113,950,274
EV/EBITDA
4.23
3.05
Interest
13,781,043
8,228,484
Interest/NOPBT
22.26%
8.93%